EnvistaNVST
About: Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.
Employees: 12,800
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
753% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $1.63M
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
12% more capital invested
Capital invested by funds: $3.37B [Q2] → $3.76B (+$397M) [Q3]
2% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 50
0% more funds holding
Funds holding: 290 [Q2] → 291 (+1) [Q3]
6% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 106
6.84% less ownership
Funds ownership: 117.81% [Q2] → 110.97% (-6.84%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Mizuho Steven Valiquette 20% 1-year accuracy 1 / 5 met price target | 7%upside $20 | Underperform Initiated | 4 Dec 2024 |
Piper Sandler Jason Bednar 50% 1-year accuracy 19 / 38 met price target | 9%downside $17 | Neutral Maintained | 31 Oct 2024 |
Baird Jeff Johnson 46% 1-year accuracy 6 / 13 met price target | 18%upside $22 | Neutral Maintained | 31 Oct 2024 |
Leerink Partners Michael Cherny 58% 1-year accuracy 19 / 33 met price target | 23%upside $23 | Market Perform Upgraded | 31 Oct 2024 |
Stifel Jonathan Bock 50% 1-year accuracy 1 / 2 met price target | 12%upside $21 | Buy Maintained | 23 Oct 2024 |
Financial journalist opinion
